Stocks · Healthcare · Medical - Devices
Abbott Laboratories ABT
$97.50 +0.84% Close, Oct 2, 2026 · NYSE · Market cap $168.71B
High qualityLow risk
Next earnings report: Oct 21, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $3.11, down 61.0% year over year.
- Revenue over the last four quarters was $46.59B, up 8.1% from a year earlier.
- Over the past year the stock returned -26.9%, behind the S&P 500 by 42.0 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth40Weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 48%
- EPS growth (TTM, YoY)Bottom 26%
- FCF growth (TTM, YoY)Top 39%
- Revenue growth, 3-year CAGRBottom 25%
- Revenue growth accelerationTop 32%
Quality80Strong
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 22%
- Gross marginBottom 42%
- Operating marginTop 16%
- Cash conversion (OCF / net income)Top 37%
- Accruals (lower is better)Bottom 36%
- Net debt / EBITDA (lower is better)Bottom 33%
- Interest coverTop 14%
Value77Positive
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 16%
- Free-cash-flow yieldTop 18%
- EBITDA / enterprise valueTop 22%
- Sales / enterprise valueTop 49%
- P/E vs own 5-year history (lower is better)Bottom 42%
Momentum32Weak
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 24%
- 6-month returnBottom 37%
- 1-year return vs S&P 500Bottom 25%
- Distance from 52-week highTop 43%
- Trend checklist (0–4)Bottom 38%
Revisions44Weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 43%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 48%
- Upside to consensus price targetBottom 30%
Stability88Strong
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 10%
- Maximum drawdown, 3 yearsTop 14%
- Beta vs S&P 500 (lower is better)Top 4%
- Net debt / EBITDA (lower is better)Bottom 33%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 6.6% | 8.1% | ↑ |
| EPS growth (YoY) | -53.4% | -61.0% | ↓ |
| Gross margin | 52.8% | 56.8% | ↑ |
| Operating margin | 17.5% | 17.0% | ↓ |
| FCF margin | 15.7% | 18.7% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 8.1% | 6.6% | ↑ | Bottom 48% |
| EPS growth (TTM, YoY) | -61.0% | -53.4% | ↓ | Bottom 26% |
| Gross margin | 56.8% | 52.8% | ↑ | Bottom 42% |
| Operating margin | 17.0% | 17.5% | ↓ | Top 16% |
| Net margin | 11.6% | 32.4% | ↓ | — |
| Free-cash-flow margin | 18.7% | 15.7% | ↑ | — |
| Return on invested capital | 6.1% | — | Top 22% | |
| Revenue growth, 3-year CAGR | 0.5% | — | Bottom 25% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.83×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -0.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 2.77×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 12.5×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 2.53%
- Net buyback yield (TTM)
- 0.97%
- Shareholder yield
- 3.50%
- Share count change, 1 year
- -0.5%
- Share count change, 3-year CAGR
- -0.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 28, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +0.8%
- Average 2-day reaction, last 8
- -1.4%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $122.00
- Target vs current price
- +25.1%
- Analysts with a rating
- 42
- Share rating Buy or Strong Buy
- 79%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 16, 2026 | +2.3% | +10.7% | +12.7% | +24.2% | — |
| Apr 16, 2026 | +0.9% | -6.0% | -9.7% | -17.5% | -9.3% |
| Jan 22, 2026 | +0.0% | -10.0% | -12.2% | -7.1% | -19.8% |
| Oct 15, 2025 | +0.0% | -2.9% | -4.3% | -4.7% | -5.5% |
| Jul 17, 2025 | +0.0% | -8.5% | -4.5% | -1.8% | +1.2% |
| Apr 16, 2025 | +1.9% | +2.8% | +2.9% | +1.9% | +4.6% |
| Jan 22, 2025 | +0.0% | +0.8% | +9.1% | +13.1% | +11.1% |
| Oct 16, 2024 | +0.8% | +1.5% | +0.1% | +0.3% | -2.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 16, 2026 | $1.31 | $1.28 | +2.3% | $12.59B |
| Apr 16, 2026 | $1.15 | $1.14 | +0.9% | $11.16B |
| Jan 22, 2026 | $1.50 | $1.50 | +0.0% | $11.46B |
| Oct 15, 2025 | $1.30 | $1.30 | +0.0% | $11.37B |
| Jul 17, 2025 | $1.26 | $1.26 | +0.0% | $11.14B |
| Apr 16, 2025 | $1.09 | $1.07 | +1.9% | $10.36B |
| Jan 22, 2025 | $1.34 | $1.34 | +0.0% | $10.97B |
| Oct 16, 2024 | $1.21 | $1.20 | +0.8% | $10.63B |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 31.4× | 30.1× | 52th | Top 16% |
| P/E (forward) | 17.7× | — | — | — |
| EV / EBITDA | 19.7× | — | — | Top 22% |
| EV / Sales | 4.21× | — | — | Top 49% |
| Free-cash-flow yield | 5.17% | — | — | Top 18% |
| Earnings yield | 3.19% | — | — | Top 16% |
P/E over the past five years
Range 15.6× – 36.7× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -26.9%
- Earnings per share growth (TTM)
- -61.0%
- Change in P/E multiple
- +114.1%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +2.7%
- 200-day average slope (20 days)
- -2.3%
- Distance from 50-day average
- -8.7%
- Distance from 200-day average
- -6.3%
- RSI (14)
- 29.7
- Relative volume
- 1.01×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 30.8%
- Volatility vs own 5-year history
- 96th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.12
- Correlation with S&P 500
- 0.08
- Current drawdown from 1-year high
- -27.6%
- Maximum drawdown, 3 years
- -41.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 27, 2021 | May 11, 2026 | -41.6% | 1096 days | Not yet recovered |
| Feb 12, 2021 | Jun 1, 2021 | -17.5% | 74 days | 66 days (Sep 2, 2021) |
| Sep 8, 2021 | Oct 4, 2021 | -10.5% | 18 days | 23 days (Nov 4, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $168.71B
- P/E (TTM)
- 31.4
- EPS, diluted (TTM)
- $3.11
- Revenue (TTM)
- $46.59B
- Dividend yield
- 3.19%
- 52-week range
- $81.97 – $135.37
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B |
| Gross profit | $23.21B | $22.32B | $20.04B | $21.32B | $24.61B |
| Operating income | $9.20B | $8.36B | $6.43B | $6.83B | $8.05B |
| Net income | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B |
| EPS (diluted) | $3.94 | $3.91 | $3.27 | $7.64 | $3.72 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.63B | $10.97B | $10.36B | $11.14B | $11.37B | $11.46B | $11.16B | $12.59B |
| Net income | $1.65B | $9.23B | $1.32B | $1.78B | $1.64B | $1.78B | $1.08B | $928.0M |
| EPS (diluted) | $0.94 | $5.27 | $0.76 | $1.01 | $0.94 | $1.02 | $0.62 | $0.53 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $10.53B | $9.58B | $7.26B | $8.56B | $9.57B |
| Capital expenditure | -$1.89B | -$1.78B | -$2.20B | -$2.21B | -$2.17B |
| Free cash flow | $8.65B | $7.80B | $5.06B | $6.35B | $7.39B |
| Dividends paid | -$3.20B | -$3.31B | -$3.56B | -$3.84B | -$4.12B |
| Net share buybacks | -$2.30B | -$3.79B | -$1.23B | -$1.29B | -$497.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $5.60B
- Total assets
- $109.22B
- Total liabilities
- $57.45B
- Total debt
- $32.61B
- Net debt
- $27.50B
- Shareholders’ equity
- $51.11B
As of Jun 30, 2026 (filed Jul 28, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Oct 15, 2026 | $0.63 | Nov 16, 2026 |
| Jul 15, 2026 | $0.63 | Aug 17, 2026 |
| Apr 15, 2026 | $0.63 | May 15, 2026 |
| Jan 15, 2026 | $0.63 | Feb 13, 2026 |
| Oct 15, 2025 | $0.59 | Nov 17, 2025 |
| Jul 15, 2025 | $0.59 | Aug 15, 2025 |
| Apr 15, 2025 | $0.59 | May 15, 2025 |
| Jan 15, 2025 | $0.59 | Feb 14, 2025 |
Short interest
- Shares sold short
- 19,911,199
- Days to cover
- 2.57
- Change vs previous report
- -10.0%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jan 2, 2013
- 5,000-for-2,399
- May 3, 2004
- 2,500-for-2,339
- Jun 1, 1998
- 2-for-1
- Jun 1, 1992
- 2-for-1
- Jun 1, 1990
- 2-for-1